Norwalk, CT, May 4, 2023 –– INTERPHEX, the premier event dedicated to pharmaceutical and biotechnology innovation, technology and knowledge from development through commercialization filled the halls of the Javits Center (April 24 – 26, 2023) for attendees to explore the latest innovations, learn from industry experts and renew or forge new business relationships.
INTERPHEX saw a robust 40% year-over-year gain in attendee numbers for 2023. Additionally, INTERPHEX featured 70 new exhibitors and an overall 15% exhibiting company increase compared to 2022.
"INTERPHEX remains the industry platform for the future of the pharmaceutical and biotechnology industries,” said Douglas Lugo, Event Director for INTERPHEX. "INTERPHEX 2023 brought together the brightest industry professionals and key suppliers to share expertise, find solutions and explore innovation in an effort to reduce costs, increase productivity and maximize efficiency. The industry continues to evolve at a rapid pace and INTERPHEX remains well-positioned to continue its leadership role in delivering access to the latest technologies and industry expertise to address challenges faced by the pharmaceutical and biotech industries."
Highlights were aplenty at INTERPHEX 2023. The 2023 Keynote Series, presented by Pharmaceutical Technology and BioPharm International, featured leading experts discussing today’s trending topics. The Keynote Series kicked off with a standing-room only audience to learn about technical advancements using mRNA modalities in oncology, infections disease and CNS indications. Another popular panel explored Organ Chip technology and what it means for drug discovery and personalized medicine.
INTERPHEX 2023 also featured several exciting Show Floor areas, including a brand-new exhibitor pavilion – the INNOVATECH Gateway Pavilion. Solidifying its mission of highlighting the full landscape of pharmaceutical and biotechnology products and innovations, INTERPHEX introduced this new pavilion featuring live demonstrations from companies representing various stages of the product development lifecycle.
Always a popular component of INTERPHEX, INTERPHEX Live, hosted and moderated by industry expert, Russ Somma, PhD. This year’s stage covered popular topics such as regulatory trends and warnings, continuous manufacturing, a deep look at post-pandemic pharmaceutical investments, contamination strategies and advancements in cell and gene therapy.
The INTERPHEX Exhibitor Awards honored advancements in technology-development, efficiency, and up-and-coming innovation. Sponsored and reviewed by American Pharmaceutical Review and Pharmaceutical Outsourcing, award categories and winners for 2023 include:
- Best in Show: IMA Life North America Inc. – INJECTA
- Best New Product/Service: DEC Group – BoMa Dosing System
- Editor’s Choice: Schunk – ADHESO Energy-Free Gripping Technology
- Best Technologies Innovation: West Pharmaceutical Services – READY PACK
- INTERPHEX Efficiency Champion: Thomas Processing – ACCELA CTC 500
- Biotech Innovation Award: PAK BioSolutions Inc. – Pilot PAK
The INTERPHEX e-Poster Hall, Sponsored by BioProcess International, was revamped this year to display all posters digitally. The e-Poster Hall showcased leading methodologies, displayed all three days of the show. The 2023 winners included:
- 1st Place: RheaVita – Implementing PAT during continuous freeze-drying allows real-time monitoring and control of relevant CQA's
- 2nd Place: Pall Corporation – Case Study: Development and Scale-up of a Helper Dependent Adenovirus (HDAd) Process Using the iCELLis® Bioreactor Platform
- 3rd Place: West Pharmaceutical Services, Inc. – Evolving Component Technologies to Meet the Needs of Large Volume Injections
- 4th Place: Entegris Life Sciences – Critical evaluation criteria for the selection of Freeze-Thaw Units for Processing of Bulk Pharmaceuticals and Intermediates.
- 5th Place: West Pharmaceutical Services, Inc. – Functional Assessment of Adeno-Associated virus stored in Daikyo Crystal Zenith® vials at ultra-cold temperatures
“We see INTERPHEX as the ideal event to share our new technology and network with relevant partners in the pharma and biotech industry,” first place e-Poster winner, Jan Van Hauwermeiren of RheaVita, said. “As we believe our technology will play a major role in implementing the Industry 4.0 standards into pharma manufacturing, showcasing during INTERPHEX gives us the opportunity to introduce our technology to leading experts.”
Fresh off the heels of the successful INTERPHEX 2023 conference, planning for INTERPHEX 2024 is already underway. The show will return to the Javits Center, April 16 – 18, 2024. Organizations interested in participating can obtain more information here.
For more information about our 2024 Show and to be notified when registration becomes available next year, fill out our registration inquiry form.
INTERPHEX has been, and continues to be, the premier pharmaceutical, biotechnology, and device development and manufacturing event where you can “Experience Science through Commercialization.” The event is based in New York and brings approximately 8,000 global industry professionals and industry leading suppliers together to “Learn it, Experience it, Procure it” through a unique combination of exhibits, demonstrations, partnering opportunities, networking and no cost technical conference to leverage quality, efficiency, and cost effectiveness in today’s ever-changing global market. INTERPHEX offers annual domestic and international industry events and educational opportunities around the world. INTERPHEX and INNOPHEX together, offer the very latest intelligence, cutting-edge technologies. and state-of-the-art innovation throughout the product development life cycle. Follow INTERPHEX on Facebook, LinkedIn, Instagram, YouTube, and Twitter. INTERPHEX continues the learning beyond the show floor. For more information, visit www.INTERPHEX.com.
About RX (Reed Exhibitions)
RX is in the business of building businesses for individuals, communities and organizations. We elevate the power of face to face events by combining data and digital products to help customers learn about markets, source products and complete transactions at approximately 400 events in 22 countries across 42 industry sectors. RX is passionate about making a positive impact on society and is fully committed to creating an inclusive work environment for all our people. RX is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.rxglobal.com
RELX is a global provider of information-based analytics and decision tools for professional and business customers. RELX serves customers in more than 180 countries and has offices in about 40 countries. It employs more than 35,000 people over 40% of whom are in North America. The shares of RELX PLC, the parent company, are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.